Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Trial Profile

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Dasatinib (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Jun 2015 Results of reverse phase protein microarray (RPMA) analysis presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 06 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top